News
Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...
Zacks Small Cap Research on MSN48m
QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate TimelineQNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback